We are a development-stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors. Our proprietary Therapeutic Vector Evolution platform enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.

(Note: The 4D Molecular Therapeutics IPO was upsized at pricing: 8.4 million shares were priced, up from 7.0 million shares in the prospectus. The IPO price was $23, the top of the new increased price range of $22 to $23 for the deal.)